Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation R; {6 }' S' b3 c- B- ?
Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline p53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-human HER2-V659E mutation showing a phenotypic convergent evolution towards HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A clinical response both symptomatic and radiologic was achieved. HER2-V659E sensitivity to lapatinib was confirmed in the laboratory.
老马你好:现需要你的帮助。& ^) o# T. T. ~' e
我每次打算换药的时候都很茫然无助,虽然在线时间那么长了,始终没掌握好该如何换药。0 e2 O; I9 x1 }" I- j' q
我家用过两次阿瓦+键泽了,效果很好,我父亲的情况下一步用什么药好?1 w, P: y' n. M3 O d1 r
我家的治疗贴http://www.yuaigongwu.com/thread-11018-1-1.html